SCHEMBL3789752

SCHEMBL3789752

[c]1cc2c(c3ccccc13)OC=CC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15797821 0.72
SCHEMBL1752671 0.70 TDP1 (0.39)
SCHEMBL5794062 0.65 CA1 (0.32)
SCHEMBL3789751 0.63 CYP2B6 (0.41)
SCHEMBL7437286 0.63 ABCG2 (0.41)
SCHEMBL23258707 0.62 CYP1A2 (0.33)
SCHEMBL578709 0.62 CYP2A6 (0.32)
SCHEMBL5935438 0.61 MAOA (0.38)
SCHEMBL11199730 0.61 TSHR (0.39)
SCHEMBL7197365 0.60 MAOA (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812051-B2 Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential ARQULE, INC. (US) 2010-10-12 US disclosed
US-20090226395-A1 Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential ARQULE, INC. (US) 2009-09-10 US disclosed
US-20060034796-A1 conjugated to polyglutamic acid for enhanced permeability and retention effect ARQULE, INC. 2006-02-16 US disclosed